Following the success of BIOMIMESYS® range of products, which accurately and physiologically reproduces the microenvironment of liver, adipose and cancerous tissues, HCS Pharma is expanding its product range with BIOMIMESYS® Brain, an exclusive and innovative system for the 3D cell culture of neuronal cells.

BIOMIMESYS® technology, provided “ready-to-use”, is easy to handle for in vitro testing. It reproduces physiological conditions thanks to a microenvironment based on Hyaluronic Acid, a product naturally present in the extracellular matrix. BIOMIMESYS® Brain includes in particular collagen IV and a cationic biopolymer that promotes the long-term culture of neural cells. In addition, its specific Young’s modulus makes its rigidity similar to that of the cerebral extracellular matrix.

All the features of BIOMIMESYS® Brain and the first validation tests are available on

Today, in vitro tests are a critical step in the development of new drugs for the pharmaceutical and dermo-cosmetic industries. They make it possible to validate the efficacy of a molecule and test its toxicity well before the costly phases of clinical testing. They also help to reduce or even replace the use of animals in preclinical tests. However, these tests are still often performed with 2D cell culture systems, which are not close enough to the human tissues to give predictive results. The transition to 3D cell culture tools is now necessary for research and industry. BIOMIMESYS® technology facilitates this transition by reproducing the cellular microenvironment, as close as possible to biological reality.

Several other products are available:

To assist its customers in the use of BIOMIMESYS® technology, HCS Pharma also proposes to develop cell culture protocols in this environment for specific cell types, on request. BIOMIMESYS® technology is protected by an exclusive patent held by HCS Pharma.

HCS Pharma

HCS Pharma is a biotechnology start-up located in Lille and Rennes, which offers research and development services to companies in the pharmaceutical, dermo-cosmetic and food industries. Its expertise: the development of new tests for in vitro pharmacology and their use in medium/high throughput screening, using the innovative high throughput cellular imaging technology called High Content Screening (HCS) and its new 3D culture technology BIOMIMESYS®.



Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.


Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: